{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:00:16Z","timestamp":1789182016759,"version":"build-2803163510"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"crossref","award":["IZ07Z0_160876\/1"],"award-info":[{"award-number":["IZ07Z0_160876\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PCEFP3_181355"],"award-info":[{"award-number":["PCEFP3_181355"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"crossref","award":["323530_177576"],"award-info":[{"award-number":["323530_177576"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1003325","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T13:30:21Z","timestamp":1600263021000},"page":"e1003325","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1716-993X","authenticated-orcid":true,"given":"Alain","family":"Amstutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bienvenu Lengo","family":"Nsakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8908-0953","authenticated-orcid":true,"given":"Fiona","family":"Vanobberghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-4543","authenticated-orcid":true,"given":"Josephine","family":"Muhairwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy Ren\u00e9e","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilo","family":"Namane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tlali","family":"Mpholo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Battegay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-6511","authenticated-orcid":true,"given":"Thomas","family":"Klimkait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-1791","authenticated-orcid":true,"given":"Niklaus Daniel","family":"Labhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"pmed.1003325.ref001","unstructured":"European AIDS Clinical Society (EACS). https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html; Guidelines Version 10.0\u2014November 2019."},{"key":"pmed.1003325.ref002","article-title":"The management of treatment-experienced HIV patients (including virologic failure and switches)","volume":"7","author":"J Cutrell","year":"2020","journal-title":"Ther Adv Infect Dis"},{"issue":"10189","key":"pmed.1003325.ref003","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"AJ Rodger","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"pmed.1003325.ref004","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel","volume":"320","author":"MS Saag","year":"2018","journal-title":"JAMA"},{"key":"pmed.1003325.ref005","unstructured":"BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals 2016 (2019 interim update) [Internet]. [cited 2020 May 8]. Available from: https:\/\/www.bhiva.org\/monitoring-guidelines"},{"key":"pmed.1003325.ref006","unstructured":"UNAIDS data 2019 | UNAIDS [Internet]. [cited 2020 Mar 8]. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2019\/2019-UNAIDS-data"},{"key":"pmed.1003325.ref007","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection; Recommendations for a public health approach\u2014Second edition June 2016 [Internet]. 2016 [cited 2016 Oct 3]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1"},{"issue":"8","key":"pmed.1003325.ref008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV Drug Resistance Detected During Low-Level Viremia Is Associated with Subsequent Virologic Failure","volume":"28","author":"LC Swenson","year":"2014","journal-title":"AIDS Lond Engl"},{"issue":"4","key":"pmed.1003325.ref009","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral Drug Resistance in HIV-1\u2013Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy","volume":"204","author":"B Taiwo","year":"2011","journal-title":"J Infect Dis"},{"issue":"2","key":"pmed.1003325.ref010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3851\/IMP2815","article-title":"Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study","volume":"20","author":"N Boillat-Blanco","year":"2015","journal-title":"Antivir Ther"},{"issue":"10","key":"pmed.1003325.ref011","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation","volume":"57","author":"C Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pmed.1003325.ref012","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","article-title":"Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients","volume":"29","author":"Antiretroviral Therapy Cohort Collaboration (ART-CC)","year":"2015","journal-title":"AIDS Lond Engl"},{"issue":"12","key":"pmed.1003325.ref013","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/cid\/ciz129","article-title":"Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure","volume":"69","author":"C Joya","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"13","key":"pmed.1003325.ref014","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","article-title":"Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy","volume":"33","author":"J Fleming","year":"2019","journal-title":"AIDS Lond Engl"},{"issue":"5","key":"pmed.1003325.ref015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/cid\/ciy989","article-title":"Persistent Low-level Viremia Predicts Subsequent Virologic Failure: Is It Time to Change the Third 90?","volume":"69","author":"A Esber","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"3","key":"pmed.1003325.ref016","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/QAI.0000000000001678","article-title":"Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment","volume":"78","author":"E Bernal","year":"2018","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"pmed.1003325.ref017","article-title":"All-Cause Mortality and Serious Non-AIDS Events in Adults with Low-Level HIV Viremia during Combination Antiretroviral Therapy: Results from a Swedish Nationwide Observational Study","author":"O Elvstam","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"2","key":"pmed.1003325.ref018","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","volume":"18","author":"LE Hermans","year":"2018","journal-title":"The Lancet Infect Dis"},{"issue":"2","key":"pmed.1003325.ref019","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1473-3099(17)30680-1","article-title":"Stepping up HIV-1 low-level viraemia surveillance in South Africa","volume":"18","author":"A Castagna","year":"2018","journal-title":"The Lancet Infect Dis"},{"issue":"1","key":"pmed.1003325.ref020","first-page":"71","article-title":"Hot News: Impact of Low-level Viremia on Treatment Outcomes During ART\u2014Is it Time to Revise the Definition of Virological Failure?","volume":"20","author":"E Poveda","year":"2018","journal-title":"AIDS Rev"},{"issue":"1","key":"pmed.1003325.ref021","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12879-018-2979-y","article-title":"SESOTHO trial (\u201cSwitch Either near Suppression Or THOusand\u201d)\u2013switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies\/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa","volume":"18","author":"A Amstutz","year":"2018","journal-title":"BMC infectious diseases"},{"key":"pmed.1003325.ref022","unstructured":"Lesotho 2016 National ART Guidelines. [Internet]. [cited 2016 Sept 15]. Available from: http:\/\/www.hivpolicywatch.org\/duremaps\/data\/guidelines\/LesothoARTGuidelinesAllChaptersandAnnex2016.pdf."},{"key":"pmed.1003325.ref023","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [cited 2020 May 10]. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"issue":"9","key":"pmed.1003325.ref024","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jclinepi.2006.12.001","article-title":"Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression","volume":"60","author":"AR Localio","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"16","key":"pmed.1003325.ref025","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1097\/QAD.0000000000000782","article-title":"Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality","volume":"29","author":"TR Glass","year":"2015","journal-title":"AIDS Lond Engl"},{"issue":"3","key":"pmed.1003325.ref026","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa","volume":"371","author":"NI Paton","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"pmed.1003325.ref027","doi-asserted-by":"crossref","first-page":"19785","DOI":"10.7448\/IAS.17.4.19785","article-title":"Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE)","volume":"17","author":"C-Y Cheng","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pmed.1003325.ref028","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1545109710385122","article-title":"The HIV Virologic Outcomes of Different Interventions Among Treatment-Experienced Patients With 2 Consecutive Detectable Low-Level Viremia","volume":"10","author":"T Pham","year":"2011","journal-title":"J Int Assoc Physicians AIDS Care Chic Ill 2002"},{"key":"pmed.1003325.ref029","doi-asserted-by":"crossref","first-page":"104255","DOI":"10.1016\/j.jcv.2019.104255","article-title":"How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis","volume":"123","author":"L Taramasso","year":"2020","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"issue":"28","key":"pmed.1003325.ref030","doi-asserted-by":"crossref","first-page":"e3985","DOI":"10.1097\/MD.0000000000003985","article-title":"Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings.","volume":"95","author":"ND Labhardt","year":"2016","journal-title":"Medicine"},{"issue":"8","key":"pmed.1003325.ref031","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label","volume":"4","author":"NI Paton","year":"2017","journal-title":"EARNEST trial. The Lancet HIV"},{"issue":"3","key":"pmed.1003325.ref032","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"M Aboud","year":"2019","journal-title":"The Lancet Infect Dis"},{"issue":"3","key":"pmed.1003325.ref033","doi-asserted-by":"crossref","first-page":"e86461","DOI":"10.1371\/journal.pone.0086461","article-title":"Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis","volume":"9","author":"PW Smit","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"pmed.1003325.ref034","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0000000000002101","article-title":"Field Suitability and Diagnostic Accuracy of the Biocentric Open Real-Time PCR Platform for Dried Blood Spot-Based HIV Viral Load Quantification in Eswatini","volume":"82","author":"B Kerschberger","year":"2019","journal-title":"Journal of Acquired Immune Deficiency Syndromes (1999)"},{"issue":"4","key":"pmed.1003325.ref035","first-page":"e01683","article-title":"Performance of a Novel Low-Cost, Instrument-Free Plasma Separation Device for HIV Viral Load Quantification and Determination of Treatment Failure in People Living with HIV in Malaysia: a Diagnostic Accuracy Study","volume":"57","author":"MD Pham","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"2","key":"pmed.1003325.ref036","doi-asserted-by":"crossref","first-page":"e1003037","DOI":"10.1371\/journal.pmed.1003037","article-title":"Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study","volume":"17","author":"LE Hermans","year":"2020","journal-title":"PLoS Med"},{"issue":"10","key":"pmed.1003325.ref037","doi-asserted-by":"crossref","first-page":"e25194","DOI":"10.1002\/jia2.25194","article-title":"Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland","volume":"21","author":"D Etoori","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"pmed.1003325.ref038","unstructured":"WHO | Update of recommendations on first- and second-line antiretroviral regimens [Internet]. WHO. World Health Organization; [cited 2020 May 10]. Available from: http:\/\/www.who.int\/hiv\/pub\/arv\/arv-update-2019-policy\/en\/"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T18:23:21Z","timestamp":1617301401000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003325"}},"subtitle":[],"editor":[{"given":"Nathan","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003325","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}